B+
Bull case
30%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
PLSE
Pulse BiosciencesFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The best post-print argument is that PLSE improved the pacing of its core AF program: management now expects NANOPULSE-AF enrollment completion in early Q4 2026, and the accompanying clinical update continued to show high procedural success and durability in feasibility patients [#PR-2026-05-04]. If execution holds, the stock can continue to trade on EP platform optionality rather than current revenue.
Posture
Defensive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-24.
What can break
Cash burn remains meaningful: Q1 2026 operating cash use was $14.6 million and quarter-end cash was $68.3 million, versus $80.7 million at year-end 2025 [#PR-2026-05-04].
Momentum
95
Value
36
Sentiment
15
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $20.00 · Bull $28.00 · Bear $13.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $62.33
Why
Momentum95 · Δ7d +4.3
Value36 · Δ7d +0.0
Sentiment15 · Δ7d 0.0
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-24.
- • Value remains the lead driver in the composite, 7D delta +0.0.
Contradictions & invalidation
- • Cash burn remains meaningful: Q1 2026 operating cash use was $14.6 million and quarter-end cash was $68.3 million, versus $80.7 million at year-end 2025 [#PR-2026-05-04].
- • Clinical and regulatory risk is still central: AF and surgical AF programs require successful pivotal enrollment, follow-up, and eventual FDA clearance or approval, and the 10-K notes regulators can delay, limit, or deny authorization [#10-K-2026-02-19].
- • The quarter did not solve the core financial debate.
Catalyst clock
2026-06-30
ATM flexibility and indicated insider buying create a mixed near-term signal
Lead driver: Value · See fundamentals
Momentum
95
8% active weight
Current posture
7d trendImproving
Δ7d
+4.3
Δ21d
-4.4
Value
36
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
15
45% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 94.9 / Value 36.3 / Sentiment 14.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$3.85B
Beta
1.77
Shares Out
72.7M
P/E (TTM) · Derived
-49.1
P/S (TTM)
11504.73
P/FCF (TTM) · Derived
-58.88
Rev YoY
-100.0%
EPS YoY
+25.1%
Gross Margin
-43.2%
Op Margin
-7007.8%
Net Debt
-$73.21M
Current Ratio
9.63
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data